Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $19.62 and last traded at $18.63, with a volume of 354,289 shares changing hands. The stock had previously closed at $19.24.

LXRX has been the topic of several recent research reports. Needham & Company LLC reiterated a “buy” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, August 11th. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 3rd. Citigroup Inc. assumed coverage on Lexicon Pharmaceuticals in a report on Tuesday, August 2nd. They set a “buy” rating and a $21.00 target price on the stock. Wedbush raised their target price on Lexicon Pharmaceuticals from $28.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, May 31st. Finally, Stifel Nicolaus raised their target price on Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. Lexicon Pharmaceuticals has an average rating of “Hold” and a consensus price target of $20.93.

The firm’s market cap is $1.93 billion. The company has a 50 day moving average price of $16.06 and a 200-day moving average price of $14.20.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/lexicon-pharmaceuticals-inc-lxrx-reaches-new-1-year-high-at-19-62.html

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04. Lexicon Pharmaceuticals had a negative return on equity of 9.03% and a negative net margin of 13.42%. The business earned $20.10 million during the quarter, compared to analysts’ expectations of $12.36 million. During the same quarter in the prior year, the firm earned ($0.27) EPS. The business’s revenue for the quarter was up 5186.8% compared to the same quarter last year. On average, equities research analysts forecast that Lexicon Pharmaceuticals Inc. will post ($1.54) EPS for the current year.

A number of institutional investors have recently modified their holdings of LXRX. Paradigm Asset Management Co. LLC purchased a new position in shares of Lexicon Pharmaceuticals during the second quarter worth about $115,000. First Mercantile Trust Co. boosted its position in shares of Lexicon Pharmaceuticals by 9.2% in the second quarter. First Mercantile Trust Co. now owns 10,700 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 900 shares during the last quarter. Alambic Investment Management L.P. purchased a new position in shares of Lexicon Pharmaceuticals during the second quarter worth about $165,000. BlackRock Group LTD boosted its position in shares of Lexicon Pharmaceuticals by 56.9% in the first quarter. BlackRock Group LTD now owns 14,217 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 5,158 shares during the last quarter. Finally, A.R.T. Advisors LLC purchased a new position in shares of Lexicon Pharmaceuticals during the first quarter worth about $174,000.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

5 Day Chart for NASDAQ:LXRX

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.